TAT-10: Progress in the [At211]-Astatination of Antibodies by Nuclephilic Approaches Using Aryliodonium Salts Precursors
We attribute this improvement to two factors: the stannane chemistry approach requires an extra purification step, and the iodonium process uses the very stable At- while the stannane requires an At+ ion.
Presented By: Francois Guerand from Centre de Recherche en Cancerologie Nantes-Angers (CRCNA), Unite INSERM 892 – CNRS 6299, Nantes, France
Written By: William Carithers, Lawrence Berkeley National Laboratory
at the 10th International Symposium on Targeted Alpha Therapy (TAT-10) May 31 - June 1, 2017 - Kanazawa, Japan.